证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Summary of Key Points from Conference Call Records Industry Overview - **Surgical Robot Industry**: The Chinese surgical robot industry is experiencing rapid development, supported by national policies and capital investment. Key technological advancements include remote operation, miniaturization, and AI assistance. The market for laparoscopic surgical robots is projected to reach 40.543 billion yuan by 2033, with a CAGR of 28.7% from 2024 to 2033 [doc id='21'][doc id='19']. Core Insights and Arguments - **Investment Opportunities in Innovative Drugs and CRO**: Despite past challenges, investment activity in innovative drugs and Contract Research Organizations (CRO) is expected to rise significantly. Business development (BD) amounts are anticipated to reach new highs, with companies like Rongchuang and Shiyao achieving attractive upfront payment ratios [doc id='3'][doc id='4']. - **Medical Device Sector Recovery**: The medical device sector is nearing the end of its inventory destocking phase, with performance expected to improve gradually in 2026. The resumption of procurement rhythms and an increase in bidding volumes are noted trends [doc id='5']. - **IVD Sector Outlook**: The In Vitro Diagnostics (IVD) sector is expected to face pressure in 2025, but conditions are projected to improve in 2026 as pricing pressures ease and policies are fully implemented [doc id='8'][doc id='9']. - **Traditional Chinese Medicine (TCM) Recovery**: The TCM sector is anticipated to bottom out in Q2 2026, with a potential recovery in 2027 driven by policy support and demand resurgence [doc id='10']. Additional Important Insights - **AI Medical and Brain-Computer Interface Technologies**: AI in healthcare is crucial for enhancing productivity, though its commercialization path remains uncertain. The brain-computer interface sector shows promise but also faces commercialization challenges [doc id='6']. - **CRO Sector Performance**: The CRO sector is showing strong order and operational performance, with companies like Kanglong Huacheng making significant progress in commercial production [doc id='11']. - **Market Dynamics for Surgical Robots**: The market for surgical robots is transitioning from an introduction phase to a growth phase, with increasing sales but slower revenue growth, indicating a structural transformation [doc id='19']. - **Regulatory Developments**: The National Medical Insurance Administration's guidelines are expected to accelerate the clinical application of surgical robots by establishing legitimate billing items [doc id='19']. Company-Specific Highlights - **Shiyao Group and AstraZeneca Collaboration**: The collaboration in the weight loss and metabolism field has set historical highs for upfront payments and total package amounts, although the overall sentiment in the sector remains subdued [doc id='7']. - **Kanglong Huacheng's Growth**: The company is expected to see a significant increase in order retention rates with the launch of its Shaoxing Phase II project, enhancing its competitive position in the CRO market [doc id='12']. - **Emerging Companies**: Companies like Tianyu and Starly are projected to enter performance inflection points this year, with significant growth potential in the raw material pharmaceutical sector [doc id='13'][doc id='14']. This summary encapsulates the key points from the conference call records, highlighting the current state and future outlook of various sectors within the healthcare and pharmaceutical industries in China.

截至2026年1月30日收盘，惠泰医疗（688617）报收于232.0元，较上周的242.5元下跌4.33%。本周，惠 泰医疗1月26日盘中最高价报245.45元。1月26日盘中最低价报231.0元。惠泰医疗当前最新总市值327.19 亿元，在医疗器械板块市值排名6/127，在两市A股市值排名647/5184。 本周关注点 深圳惠泰医疗器械股份有限公司于2025年12月9日至2026年1月28日期间，通过集中竞价交易方式累计回 购股份1,015,738股，占公司总股本的0.7202%，回购价格区间为231.00元/股至264.27元/股，支付资金总 额24,995.13万元。本次回购股份用于员工持股计划或股权激励，资金来源为公司自有资金，回购方案已 实施完毕。回购后公司股权分布仍符合上市条件，未导致控制权变更。已回购股份将在三年内按规定转 让，若未完成转让将依法注销。 公司公告汇总：惠泰医疗回购股份1,015,738股，占总股本0.7202%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总 ...

Group 1 - The company is currently selling vascular intervention and some electrophysiological mapping consumables to the EU market through a distribution model [1] - The relevant products have obtained CE certification [1] - The revenue from this market accounts for a relatively low proportion of the company's overall revenue [1]

Military and Geopolitical Developments - The US Central Command announced that the Ninth Air Force will conduct air force readiness exercises in the Middle East, aimed at enhancing rapid deployment capabilities [2] - The USS Abraham Lincoln Carrier Strike Group has entered the Middle East, and the US has informed Israel about military preparations against Iran, expected to be completed within two weeks [2] - Iran's Revolutionary Guard Navy officials stated they have achieved real-time monitoring of the Strait of Hormuz and are prepared for any potential conflict, asserting they do not seek war but are ready for a response [2] Financial Markets Overview - US stock markets showed mixed results, with the Dow Jones down 0.83%, while the Nasdaq rose by 0.91% and the S&P 500 increased by 0.41% [3] - Major tech stocks mostly rose, with Amazon up 2.63%, Microsoft up 2.19%, and Apple up 1.12%, while Tesla fell nearly 1% [3] - The Nasdaq Golden Dragon China Index increased by 0.48%, with mixed performances among popular Chinese stocks [3] Commodity Prices - International oil prices rose, with WTI crude oil futures closing at $62.57 per barrel, up 3.20%, and Brent crude oil futures at $66.70 per barrel, up 2.98% [3] - Spot gold increased by 3.45%, reaching $5,181.04 per ounce, with a peak at $5,190.06, marking a historical high [3] - Spot silver rose by 7.97%, priced at $112.14 per ounce [3] Currency and Exchange Rates - The US Dollar Index fell to 95.775, hitting a low of 95.510, the lowest since early 2022 [4] - The offshore RMB was quoted at 6.9321, while the onshore RMB was at 6.9545 [5] Corporate Announcements - Anta Sports announced plans to acquire a 29.06% stake in Puma for €15.06 billion (approximately 123 billion RMB), aiming to become its largest shareholder [15] - Micron Technology plans to invest $24 billion in Singapore over the next decade to expand NAND flash memory production, creating approximately 1,600 jobs [16] - DeepSeek launched a new AI model, DeepSeek-OCR 2, which can interpret images in a human-like logical sequence, enhancing its visual understanding capabilities [13]

Key Highlights - Tianqi Co., Ltd. participated in financing for Galaxy General Robotics, acquiring up to 0.38% equity [1] - Hualan Vaccine has no vaccine products available for the prevention of Nipah virus [1] - Aisen Co., Ltd. plans to invest 2 billion yuan to build an integrated circuit materials manufacturing base in East China [1] - Beixin Road and Bridge won a contract for a project worth 1.221 billion yuan [1] - Yongding Co., Ltd. expects a net profit increase of 225.66% to 388.48% in 2025 [1] - Puxin Co., Ltd. intends to acquire a 5% stake in Liyuan Fluororesin for 240 million yuan [1] - Huatai Medical has repurchased 0.7202% of its shares [1] - Dayi Long plans to reduce its stake by no more than 3% [1] - Dongcai Technology's actual controller and vice chairman, Xiong Haitao, has been detained [1] - Yichang Technology's actual controller, Xiong Haitao, is under investigation and has been detained [1] Project Investments - Nord Co., Ltd. plans to invest 168 million yuan to upgrade production line equipment for Qinghai Electronics [1] - Aisen Co., Ltd. is set to invest 2 billion yuan in a manufacturing base for integrated circuit materials [1] Contract Awards - Jintanglang Co., Ltd. won a contract for the interior decoration and weak current intelligent engineering of a new hotel project [1] - Beixin Road and Bridge secured a contract worth 1.221 billion yuan [1] - Huakang Clean won a project worth 54.88 million yuan [1] Earnings Forecasts - New Meixing Co., Ltd. expects a net profit growth of 160.76% to 204.96% in 2025 [1] - Hongxin Electronics anticipates a net profit of 110 million to 150 million yuan in 2025, a year-on-year increase of 93.61% to 164.01% [1] - Yongding Co., Ltd. forecasts a net profit increase of 225.66% to 388.48% in 2025 [1] - Zhenlei Technology expects a net profit increase of 529.64% to 642.26% in 2025 [1] - Ningbo Fubang anticipates a net profit growth of 3099.59% to 4379.43% in 2025 [1] Share Acquisitions - Puxin Co., Ltd. plans to acquire a 5% stake in Liyuan Fluororesin for 240 million yuan [1] - Yingxin Development intends to acquire 60% equity in Changxing Semiconductor [1] Share Buybacks - Jingji Zhino has repurchased 5.438 million shares [2] - Huatai Medical has repurchased 0.7202% of its shares [2] Share Reductions - Baida Precision plans to reduce its stake by no more than 2% [2] - Dayi Long intends to reduce its stake by no more than 3% [2] - Zhishang Technology's Liu Dongsheng and Liu Dongli plan to reduce their stakes by no more than 3% [2] - Shichuang Securities' City Power plans to reduce its holdings by no more than 27.245 million A-shares [2] - Pianzaihuang's Jiulongjiang Group plans to increase its holdings by 300 million to 500 million yuan [2] Other News - Dongcai Technology's actual controller and vice chairman, Xiong Haitao, has been detained [2] - Jingpin Special Equipment has been banned from participating in procurement activities for military supplies for three years [2] - Yichang Technology's actual controller, Xiong Haitao, is under investigation and has been detained [2]

Summary of Key Points Core Viewpoint - On January 28, a total of 14 companies announced 15 stock repurchase updates, indicating a trend of companies engaging in buyback programs to enhance shareholder value [1]. Group 1: First Disclosure of Buyback Plans - Two companies, Greenmei and Davi Co., disclosed their stock repurchase plans for the first time, with proposed buyback amounts not exceeding 3.03 million and 0.23 million respectively [1]. Group 2: Approval of Buyback Plans by Shareholders - Three companies, New Open Source, Guangdong Hongtu, and Guangji Pharmaceutical, had their buyback plans approved by shareholders, with the highest proposed repurchase amounts being 50 million, 18.10 million, and 0.42 million respectively [1]. Group 3: Progress of Buyback Implementation - The companies with the highest buyback amounts in progress include Heng Rui Pharmaceutical, Jingji Agricultural, and Xingfa Group, with repurchase amounts of 605 million, 94.46 million, and 65.54 million respectively [1]. Group 4: Completed Buybacks - The companies that have completed their buybacks with the highest amounts are Huitai Medical, Xiye Co., and Aopu Technology, with completed repurchase amounts of 250 million, 7.01 million, and 0.85 million respectively [1].

Group 1 - The company Huatai Medical announced that it has repurchased approximately 1.02 million shares, accounting for 0.7202% of its total share capital of approximately 141 million shares [1] - The highest price for the repurchased shares was 264.27 RMB per share, while the lowest price was 231 RMB per share [1] - The total amount spent on the share repurchase was approximately 250 million RMB, and the repurchase plan has been completed [1] Group 2 - International gold prices have surpassed 5000 USD, marking a 280% increase over the past seven years [1] - Experts suggest that the future trajectory of gold prices will depend significantly on the US dollar, as well as factors such as the international monetary system, interest rate cuts, and technological revolutions [1]

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-002 深圳惠泰医疗器械股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/10，由公司董事会提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 月 2025 9 | 12 | 月 | 年 | 10 | 日 8 | | 预计回购金额 | 2亿元~2.5亿元 | | | | | | | 回购价格上限 | 315元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 1,015,738股 | | | | | | | 实际回购股数占总股本比例 | 0.7202 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]